Catabasis Pharmaceuticls Inc. (NASDAQ:CATB) shares traded down 5% during trading on Friday . The stock traded as low as $5.02 and last traded at $5.18, with a volume of 68,111 shares traded. The stock had previously closed at $5.45.

Several research analysts have commented on the company. Zacks Investment Research lowered Catabasis Pharmaceuticls from a “buy” rating to a “hold” rating in a research report on Monday, July 18th. Wedbush reiterated an “outperform” rating and issued a $17.00 target price (down from $27.00) on shares of Catabasis Pharmaceuticls in a research note on Tuesday, June 7th. Oppenheimer Holdings Inc. reiterated a “buy” rating on shares of Catabasis Pharmaceuticls in a research note on Saturday, May 14th. Finally, Cowen and Company reiterated a “buy” rating on shares of Catabasis Pharmaceuticls in a research note on Wednesday, June 8th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Catabasis Pharmaceuticls presently has a consensus rating of “Buy” and an average price target of $19.05.

The company’s market cap is $77.95 million. The firm’s 50-day moving average is $3.85 and its 200 day moving average is $4.99.

Catabasis Pharmaceuticls (NASDAQ:CATB) last announced its quarterly earnings data on Thursday, May 12th. The company reported ($0.61) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.64) by $0.03. Analysts predict that Catabasis Pharmaceuticls Inc. will post ($2.52) earnings per share for the current fiscal year.

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.